Being diagnosed with inflammatory bowel disease (IBD) often means entering a new world of specialist appointments, monitoring and treatment decisions. Understanding how gastroenterology care is structured can help you feel more prepared and engaged in managing your condition.
What gastroenterology care involves
Gastroenterology is the branch of medicine focused on the digestive system. For people with IBD, care typically centres on a consultant gastroenterologist who specialises in Crohn’s disease and ulcerative colitis. You may also work with an IBD specialist nurse, a dietitian and sometimes a colorectal surgeon if complications require surgical input.
The goal is not just to control symptoms, but to reduce inflammation, prevent long-term damage and minimise complications such as strictures, fistulas or surgery. This “treat to target” approach means treatment decisions are guided by objective measures of inflammation rather than symptoms alone.
Your first gastroenterology appointment
Your first appointment usually involves a detailed review of your symptoms, medical history, family history and previous investigations. The consultant will ask about bowel movements, abdominal pain, weight changes and any extra-intestinal symptoms such as joint pain or skin changes.
You will likely be examined, and the consultant may arrange blood tests, stool tests and imaging or endoscopy to confirm diagnosis, assess disease extent and rule out other conditions. If already diagnosed, the focus shifts to understanding current disease activity and planning treatment.
Monitoring and follow-up
Regular monitoring is essential. Blood tests measure inflammatory markers such as C-reactive protein (CRP) and check for anaemia, nutritional deficiencies and drug safety. Faecal calprotectin stool tests detect gut inflammation without invasive procedures.
Endoscopy remains the gold standard for assessing mucosal healing, the resolution of visible inflammation and ulceration in the gut lining. Mucosal healing is associated with better long-term outcomes, including fewer flares and reduced need for surgery. Depending on your disease and treatment, you may have colonoscopy or flexible sigmoidoscopy every one to three years, or more frequently if disease is difficult to control.
Imaging such as MRI enterography or ultrasound assesses the small bowel, which is not accessible by standard colonoscopy, and monitors for complications like abscesses or fistulas.
Treatment decisions and shared care
Treatment is individualised based on disease type, location, severity, response to previous treatments and personal preferences. Initial treatment may involve aminosalicylates (such as mesalazine) for mild ulcerative colitis, or corticosteroids for moderate to severe disease. Steroids induce remission but are unsuitable for long-term use due to side effects, so the focus is finding steroid-free maintenance therapy.
Immunosuppressants such as azathioprine or methotrexate, and biological therapies such as anti-TNF agents (infliximab or adalimumab) or anti-integrin therapies (vedolizumab), are used for more active disease. These drugs dampen the immune response driving gut inflammation. Newer therapies, including JAK inhibitors (tofacitinib or upadacitinib), offer additional options.
Your gastroenterologist will discuss risks and benefits of each treatment, including side effects and monitoring requirements. Shared decision making is important in modern IBD care, meaning you are encouraged to ask questions and participate in choosing a treatment plan that fits your life and goals.
The role of the IBD nurse
IBD specialist nurses provide ongoing support between consultant appointments, help coordinate care and are often your first point of contact if symptoms change. They offer advice on managing flares, adjusting medications under agreed protocols and accessing services such as dietetics or psychological support.
Many IBD nurses run telephone or email helplines and conduct monitoring appointments or infusion clinics for biological therapies. Building a relationship with your IBD nurse can make a significant difference to how supported you feel.
When surgery is considered
Most people with IBD are managed with medication, but surgery is sometimes necessary. In ulcerative colitis, surgery typically involves removing the colon (colectomy) and is considered if medical treatment fails, if there are complications such as severe bleeding or perforation, or if there is dysplasia or cancer. In Crohn’s disease, surgery is usually reserved for complications such as strictures, fistulas or abscesses unresponsive to medical therapy.
If surgery is discussed, you will meet with a colorectal surgeon specialising in IBD. They will explain the procedure, recovery expectations and long-term disease management implications. For many people, surgery can significantly improve quality of life, although it does not cure Crohn’s disease and inflammation can recur.
Practical takeaways
- Bring a list of your current symptoms, medications and questions to every appointment.
- Keep a record of your blood and stool test results to track trends over time.
- Ask your IBD team how often you should expect monitoring and what the treatment targets are.
- Use your IBD nurse as a resource for day-to-day questions between consultant appointments.
- If considering changing or stopping a treatment, discuss it with your team first.
- Remember that symptoms do not always reflect inflammation levels, which is why objective monitoring is important.
Conclusion
Gastroenterology care for IBD is a long-term partnership between you and your clinical team. It involves regular monitoring, individualised treatment and ongoing communication to keep inflammation under control and prevent complications. Understanding what to expect at appointments, how decisions are made and who to contact when things change can help you feel more confident in managing your condition.
References
- Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110(9):1324-1338. doi:10.1038/ajg.2015.233
- Neurath MF, Travis SP. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut. 2012;61(11):1619-1635. doi:10.1136/gutjnl-2012-302830
- Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570-1583. doi:10.1053/j.gastro.2020.12.031
- Magro F, Gionchetti P, Eliakim R, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis. 2017;11(6):649-670. doi:10.1093/ecco-jcc/jjx008
- Gomollón F, Dignass A, Annese V, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: Part 1: diagnosis and medical management. J Crohns Colitis. 2017;11(1):3-25. doi:10.1093/ecco-jcc/jjw168
- Kennedy NA, Jones GR, Lamb CA, et al. British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic. Gut. 2020;69(6):984-990. doi:10.1136/gutjnl-2020-321244
- Danese S, Vuitton L, Peyrin-Biroulet L. Biologic agents for IBD: practical insights. Nat Rev Gastroenterol Hepatol. 2015;12(9):537-545. doi:10.1038/nrgastro.2015.135
This article is intended for informational and educational purposes only. It does not constitute medical advice and should not be used as a substitute for professional medical guidance, diagnosis, or treatment.